He is a member of the Pharmacology and Molecular Mechanisms Group of the EORTC (European Organisation for Research and Cancer Treatment) from 1988 to now. The main fields of interest where the research is carried out are: a)Clinica l pharmacology, Phase I and II studies of new drugs b)Drug analysis, pharmacokinetics and pharmacodynamics studies c)Development of innovative methods for the measurement of anti-tumour drugs (HPLC-u MS/MS-MALDI imaging mass spectrometers). d)Clinical studies in GCP and GLP e)Pharmacokinetics, toxicokinetics and metabolic studies o f new drugs in animal models f)Pharmacokinetic drug interaction studies He is the author or co-author of over a hundred scientific publications on clinical and preclinical antitumour chemotherapy topics.